Brands: Eligard
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| TOLMAR Inc. | unknown | 4 | SUPPLYING |
| NorthStar RxLLC | relabeler | 1 | SUPPLYING |
| UBI Pharma Inc. | unknown | 1 | SUPPLYING |
| PAI Holdings, LLC dba PAI Pharma | unknown | 1 | SUPPLYING |
| Amneal Pharmaceuticals LLC | generic | 1 | SUPPLYING |
| Meitheal Pharmaceuticals Inc. | generic | 1 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Leuprolide Acetate Injection — reported in shortage by Amneal Pharmaceuticals. Therapeutic category: Oncology.
Leuprolide Acetate Injection — reported in shortage by Amneal Pharmaceuticals. Therapeutic category: Oncology.
Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product. — Recalling firm: Tolmar, Inc. — Nationwide in the US.
